| ViraferonPeg (peginterferon-α-2b) / Merck (MSD) |
NCT00248339: Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection |
|
|
| Completed | 3 | 150 | US | Peginterferon-alpha-2b (PEG-Intron), Ribavirin, Epoetin-alpha (Procrit) | Virginia Commonwealth University, Ortho Biotech, Inc. | Hepatitis C | 07/05 | 07/05 | | |
NCT00811967: Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED) |
|
|
| Terminated | 3 | 50 | NA | PegIntron (peginterferon alfa-2b; SCH 54031), SCH 54031, Rebetol (ribavirin; SCH 18908), SCH 18908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Liver Cirrhosis | 05/06 | 05/06 | | |
P02370, NCT00039871: PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study ) |
|
|
| Completed | 3 | 2333 | NA | PegIntron (peginterferon alfa-2b; SCH 54031), SCH 54031, REBETOL (ribavirin; SCH 18908) | Merck Sharp & Dohme LLC | Hepatitis, Hepatitis C, Chronic, Fibrosis, Liver Cirrhosis | 09/07 | 09/07 | | |
NCT00081770: Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) |
|
|
| Completed | 3 | 4469 | NA | PegIntron (peginterferon alfa-2b; SCH 54031), PegIntron, REBETOL (ribavirin; SCH 18908), REBETOL [the Schering-Plough brand name for ribavirin], PEGASYS (peginterferon alfa-2a), PEGASYS, COPEGUS (ribavirin), COPEGUS [the Hoffman-La Roche brand name for ribavirin] | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 11/07 | 11/07 | | |
NCT00104052: Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1) |
|
|
| Completed | 3 | 107 | NA | peginterferon alfa-2b (PEG2b) (SCH 54031), PEG-Intron (SCH 54031), ribavirin (SCH 18908), REBETOL (SCH 18908) | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 11/07 | 11/07 | | |
P02569, NCT00048724: Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study ) |
|
|
| Completed | 3 | 631 | NA | peginterferon alfa-2b (SCH 54031), PegIntron | Merck Sharp & Dohme LLC | Chronic Hepatitis C, Cirrhosis | 04/08 | 04/08 | | |
NCT00302081 / 2004-000820-34: Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548) |
|
|
| Completed | 3 | 696 | NA | peginterferon alfa-2b (SCH 54031), PegIntron (SCH 54031), ribavirin (SCH 18908), REBETOL (SCH 18908) | Merck Sharp & Dohme LLC, Integrated Therapeutics Group | Hepatitis C, Chronic | 04/08 | 04/08 | | |
NCT00441584: The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833) |
|
|
| Terminated | 3 | 117 | NA | PegIntron (peginterferon alfa-2b), SCH 54031, PEG-Intron, PegIntron, ViraferonPeg, peginterferon alfa-2b, Rebetol (ribavirin), SCH 18908, Rebetol, REBETOL, ribavirin | Merck Sharp & Dohme LLC, Integrated Therapeutics Group | Hepatitis C, Chronic | 06/08 | 06/08 | | |
NCT00371761: PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278) |
|
|
| Completed | 3 | 25 | NA | Pegylated interferon alfa-2b (PegIntron), SCH 54031, Peg-Intron, Adefovir dipivoxil (adefovir), Hepsera | Merck Sharp & Dohme LLC | Hepatitis B, Chronic (CHB) | 02/09 | 02/09 | | |
NCT00686790: Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) |
|
|
| Completed | 3 | 68 | NA | Peginterferon alfa-2b (PegIntron, SCH 54031), SCH 54031, PegIntron | Merck Sharp & Dohme LLC | Hepatitis D, Chronic, Hepatitis B, Chronic | 05/09 | 05/09 | | |
NCT00378599: Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) |
|
|
| Completed | 3 | 125 | NA | Combination of (a) pegylated interferon alfa-2b and (b) rebetol, (a) SCH 54031, PEG-Intron, (b) SCH 18908, Rebetol | Merck Sharp & Dohme LLC | Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis | 07/09 | 07/09 | | |
NCT00049842: Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) |
|
|
| Completed | 3 | 540 | NA | peginterferon alfa-2b (SCH 54031) | Merck Sharp & Dohme LLC | Chronic Hepatitis C, Liver Fibrosis | 10/09 | 10/09 | | |
NCT00423800: Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED) |
|
|
| Terminated | 3 | 56 | NA | Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV), PEGETRON® combination therapy, (a) SCH 54031, PEGETRON® (peginterferon alfa-2b) Powder for Solution, (b) SCH 18908, PEGETRON® (ribavirin) Capsules | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 10/09 | 10/09 | | |
NCT00759109: Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) |
|
|
| Completed | 3 | 150 | NA | Peginterferon alfa-2b, PegIntron, Pegylated Alfa-2b, SCH 054031, Observation (no treatment) | Merck Sharp & Dohme LLC | Carcinoma, Hepatocellular | 11/09 | 11/09 | | |
NCT00536263: PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) |
|
|
| Completed | 3 | 671 | NA | pegylated interferon alpha-2b | Merck Sharp & Dohme LLC | Hepatitis B, Chronic | 11/09 | 11/09 | | |
NCT00708500 / 2007-005151-42: Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) |
|
|
| Completed | 3 | 404 | NA | Boceprevir (SCH 503034), Pegylated interferon alfa-2b (SCH 54031), PegIntron, PEG2b, Ribavirin (SCH 18908), Rebetol, RBV, Boceprevir placebo | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 04/10 | 04/10 | | |
|
|
|
|
|
|
| Completed | 3 | 1472 | NA | Peginterferon alfa-2b (PEG), PegIntron, PEG, SCH 54031, Ribavirin (RBV), Rebetol, RBV, SCH 18908, Placebo, Boceprevir, SCH 503034, Victrelis | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 05/10 | 05/10 | | |
|
|
|
|
|
|
|
NCT00687219: Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) |
|
|
| Completed | 3 | 102 | NA | Peginterferon alfa-2b, SCH 054031, Ribavirin, SCH 018908 | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Liver Cirrhosis | 10/10 | 10/10 | | |
NCT00686517: Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137) |
|
|
| Completed | 3 | 130 | NA | Pegylated interferon alfa-2b, SCH 54031, PegIntron, Ribavirin, SCH 18908, Rebetol | Merck Sharp & Dohme LLC, Bioikos Ambiente Srl | Hepatitis C | 12/10 | 12/10 | | |
NCT00686881: Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773) |
|
|
| Terminated | 3 | 261 | NA | Peginterferon alfa-2b (PegIFN-2b), SCH 054031, Pegylated interferon alfa-2b, Comparator: Stronger neo minophagen C (SNMC) | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 02/11 | 02/11 | | |
NCT01366638: A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 3 | 79 | Japan | TMC435, Peginterferon alfa-2b (pegIFN alfa-2b), PEGINTRON, Ribavirin (RBV), REBETOL | Janssen Pharmaceutical K.K. | Hepatitis C, Chronic | 11/12 | 11/12 | | |
|
|
|
NCT00761735 / 2004-000558-22: 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2) |
|
|
| Completed | 3 | 94 | NA | Peginterferon alfa-2b, PEG-Intron®, Ribavirin, REBETOL® | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 01/13 | 01/13 | | |
MK-7009-044, NCT01405937: Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment |
|
|
| Completed | 3 | 51 | NA | vaniprevir, MK-7009, peg-IFN, PegIntron®, ribavirin, REBETOL® | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 02/13 | 03/13 | | |
MK-7009-045, NCT01405560: Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment |
|
|
| Completed | 3 | 42 | NA | Vaniprevir, MK-7009, peg-IFN, PegIntron, ribavirin, REBETOL® | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 03/13 | 03/13 | | |
MK-7009-043, NCT01370642: Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants |
|
|
| Completed | 3 | 294 | NA | vaniprevir, MK-7009, Placebo to vaniprevir, Peg-IFN, PegIntron, ribavirin, REBETOL® | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 07/13 | 03/14 | | |
ViZIR, NCT02099604: Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C |
|
|
| Withdrawn | 3 | 0 | RoW | Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin, Vidrop, PegIntron, Rebetol | ANRS, Emerging Infectious Diseases, Institut Pasteur | Chronic Hepatitis C | 04/14 | 04/14 | | |
NCT00381017 / 2005-003876-39: Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371) |
|
|
| Withdrawn | 3 | 0 | US | Peg interferon alpha-2b | Merck Sharp & Dohme LLC, Integrated Therapeutics Group | Hepatitis C, Liver Cirrhosis, HIV Infections | | | | |
NCT01390844: Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) |
|
|
| Completed | 3 | 282 | NA | Boceprevir (BOC), SCH 503034, Victrelis, Placebo to boceprevir, Peginterferon alfa-2b (PEG), PegIntron, SCH 054031, Redipen, Ribavirin (RBV), Rebetol, SCH 018908, Cross-Over Boceprevir Treatment | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 06/15 | 06/15 | | |
MK-3034-107, NCT01945294: Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 |
|
|
| Completed | 3 | 257 | NA | Boceprevir, MK-3034, Peg-interferon alfa-2b, PegIntron, Ribavirin, Rebetol | Merck Sharp & Dohme LLC | Hepatitis C, Chronic | 08/15 | 11/15 | | |
NCT02103439: An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients |
|
|
| Completed | 3 | 140 | RoW | Algeron, Cepeginterferon alfa-2b, PegIntron, peginterferon alfa-2b | Biocad | Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection | 08/15 | 08/15 | | |
MK-4031-376, NCT01641926: A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) |
|
|
| Terminated | 3 | 402 | NA | PEG-Intron™, SCH 054031, Pegylated interferon alfa-2b, PEGASYS™, Pegylated interferon alfa-2a | Merck Sharp & Dohme LLC | Hepatitis B, Chronic | 01/16 | 01/16 | | |
NCT02204475: Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) |
|
|
| Withdrawn | 3 | 0 | US | Grazoprevir/Elbasvir, Boceprevir, PegIntron, Pegylated Interferon, Ribavarin | Merck Sharp & Dohme LLC | Hepatitis C | 06/16 | 09/16 | | |
NCT01641666: Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599) |
|
|
| Withdrawn | 3 | 0 | RoW | Boceprevir, SCH 503034, Peginterferon Alfa-2b 1.5 mcg/kg/week, Pegintron®, Rebetol®, Ribavirin | Merck Sharp & Dohme LLC | Chronic Hepatitis C | 09/16 | 09/16 | | |
NCT01740089: Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C |
|
|
| Completed | 2/3 | 150 | RoW | Algeron, cepeginterferon alfa-2b, PegIntron, Peginterferon alfa-2b, Ribavirin | Biocad | Hepatitis, Hepatitis C | 07/12 | 12/13 | | |
NCT00323804 / 2005-002937-11: Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. |
|
|
| Completed | 2/3 | 372 | Europe | Peginterferon alfa-2b, Ribavirin, Ribavirin-Placebo | ANRS, Emerging Infectious Diseases, Merck Sharp & Dohme LLC, Rennes University Hospital | Hepatitis C, Chronic, Liver Fibrosis | 02/13 | 03/13 | | |
NCT00689390 / 2006-006529-25: Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063) |
|
|
| Terminated | 2/3 | 1954 | NA | Boceprevir, SCH 503034, Narlaprevir, SCH 900518, Peginterferon alfa-2b, PEG-Intron®, SCH 054031, Ribavirin, Rebetol®, Blood/Plasma Collection | Merck Sharp & Dohme LLC | Hepatitis C, Chronic, Hepacivirus | 10/14 | 10/14 | | |
|
NCT01871662: Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C |
|
|
| Withdrawn | 2/3 | 0 | RoW | Legalon® SIL (Silibinin), Pegylated interferon alfa2b, PEG-INTRON®, Ribavirin, REBETOL® | Rottapharm | Hepatitis C, Chronic | 02/16 | 02/16 | | |
